Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial

Podobne knjige/članki

• Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
  od: Cavender, Matthew A., et al.
  Izdano: (2016)
• Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
  od: O’Donoghue, Michelle L., et al.
  Izdano: (2016)
• The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX
  od: Yong, Celina M., et al.
  Izdano: (2019)
• The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
  od: Gutierrez, J. Antonio, et al.
  Izdano: (2016)
• Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
  od: Stone, Gregg W, et al.
  Izdano: (2018)